St. Gallen International BCa Conference
Representing Slovakia at the St. Gallen International Breast Cancer Conference
The St. Gallen International Breast Cancer Conference is one of the most prestigious global events, bringing together leading oncologists and experts in early breast cancer. The conference culminates in the renowned St. Gallen Consensus Session,which defines international recommendations for the diagnosis and treatment of early breast cancer worldwide.
This year, the conference is significant for us, as we are preparing a clinical study for patients with triple-negative breast cancer (TNBC) in the preoperative (neoadjuvant) setting, treated with the innovative Keynote-522 therapy (a combination of chemotherapy and immunotherapy). The lectures,partner meetings, and expert discussions at St. Gallen provide invaluable insights for our upcoming work.
Our delegation is larger this year, and for the first time, we are joined by our new Chief Medical Officer, David Eberhard. We are delighted that our young scientists at MultiplexDX International have the opportunity not only to learn but also to represent Slovak science at such a prestigious conference.
We are also meeting with our colleagues from our sister company StratifAI, represented by CEO Omar El Nahhas. Together, we recently published a research article in Nature Communications and continue to collaborate on multiple innovative projects that combine artificial intelligence with breast cancer diagnostics. We see great potential in this partnership.
This has been time exceptionally well spent. Many presentations confirm that our Multiplex8+ diagnostic test is highly innovative and has the potential to help many oncology patients receive the proper treatment at the right time.Discussions with experts also indicate that, following successful prospective clinical validation, Multiplex8+ is likely to be embraced by the global oncology community.
This recognition inspires and motivates us to keep pushing forward.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
